General Information of Drug (ID: DMHQNVR)

Drug Name
YH001
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D1YXQ4

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Aggressive cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 2.73E-01 0.02 0.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04699929) A Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability,Efficacy and Pharmacokinetics of YH001 in Subjects With Advanced Solid Tumors. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Biocytogen